RVV — Revive Therapeutics Share News
0.000.00%
Last trade - 00:00- CA$8.71m
- CA$8.71m
Brief: Revive Therapeutics Announces Published Research Results On Bucillamine As Potential Inhibitor Of COVID-19 Delta Variant
Brief: Pharmather Announces Positive Research Results For Psilocybin Microneedle Patch
Brief: Revive Therapeutics Enters Into Research Collaboration Agreement With Pharmather
Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In COVID-19
Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In COVID-19 With Planned Completion And Emergency Use Authorization Request
Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19 With Plans On Emergency Use Access
Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In Covid-19
Brief: Revive Therapeutics Announces Irb Approval For Phase 3 Clinical Trial Protocol For Bucillamine In Covid-19
Brief: Revive Therapeutics Announces Submission Of Irb Approval For Phase 3 Clinical Trial Protocol For Bucillamine In Covid-19
Brief: Revive Therapeutics To Expand Phase 3 Clinical Trial For Bucillamine In COVID-19 In Asia-Pacific & Canada
Brief: Revive Therapeutics Expects To Engage Up To 10 Clinical Trial Sites In U.S.
Brief: Revive Therapeutics Expands Research Partnership For Novel Formulation Development And Clinical Research Of Psilocybin
Brief: Revive Therapeutics Retains Pharm-Olam To Advance Clinical Study For Bucillamine In Treatment Of Infectious Diseases, Including Covid-19
Brief: Revive Therapeutics Explores The Use Of Bucillamine As A Novel Treatment For Infectious Diseases Including Covid-19
Brief: Revive Therapeutics To Pursue The Psychedelic Market With Agreement And Investment In Red Light Holland Financing
Brief: Revive Therapeutics To Acquire Greeninsightz Limited And Brokered Private Placement
Brief: Revive Therapeutics Announces Approval Of CSE Listing